Form 4: Enliven Therapeutics CFO Benjamin Hohl Executes Option and Sells Shares

Benjamin Hohl, CFO of Enliven Therapeutics, exercised options to acquire 1,000 shares of common stock at $2.48 and sold 1,000 shares at a weighted average price of $22.5045.

Summary

• On March 24, 2025, Benjamin Hohl, the CFO of Enliven Therapeutics, exercised options to acquire 1,000 shares of common stock at a price of $2.48 per share.
• Simultaneously, Hohl sold 1,000 shares of common stock at a weighted average price of $22.5045, with individual sales ranging from $22.50 to $22.51.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 26, 2023.
• Following these transactions, Hohl directly owns 23,000 shares of common stock and holds options for 131,806 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports routine transactions under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the trades mitigates any significant concerns.

Key Dates

Keywords

Enliven Therapeutics, ELVN, Benjamin Hohl, CFO, Form 4, Stock Options, Share Sale, Rule 10b5-1 Trading Plan, Insider Trading